pharmaceuticals
Healthcare
Analysis: M&A deal value in healthcare and pharma hits record high in Jan-June
Merger and acquisitions (M&As) deal value in the healthcare and pharmaceutical space hit a record high in Jan-June, crossing the ......
Healthcare
Healthcare 2021: Healthtech shines; diagnostics, hospitals keep up with IPOs, M&As
India’s healthtech segment made great strides in 2021, with the landmark acquisition of a listed company - Thyrocare Technologies, by ......
Healthcare
Flashback 2020: Vaccine makers, healthtech in spotlight as Covid-19 rages
Indian vaccine makers took centre stage in 2020 as the country and emerging markets pinned their hopes on them to ......
Healthcare
ChrysCapital returns as investor in another pharma firm after taking it public
Homegrown private equity firm ChrysCapital has returned to invest in a pharmaceutical company that it had helped launch on the ......
Healthcare
Flashback 2019: Single-specialty, regional hospitals steal the thunder in healthcare
A strong revival of investor interest in eye-care clinics, big-ticket deals in the dialysis, fertility and oncology segments and a ......
Healthcare
M&A activity in healthcare softens, PE dealmaking steady in Q2
Merger and acquisition activity in India's healthcare sector has slowed in recent quarters from last year when Malaysian company IHH ......
Healthcare
How much did SAIF Partners, ChrysCapital make from stake sale in drugmaker?
Venture capital and growth-equity investor SAIF Partners as well as private equity firm ChrysCapital have sold stakes in an Indian ......
Healthcare
Quadria Capital hits the road for new healthcare PE fund
Quadria Capital, a private equity firm which focuses on South- and Southeast Asia, has hit the road to raise its ......
Finance
ChrysCapital checks out of PIPE portfolio firm with high returns
Homegrown private equity firm ChrysCapital has fully exited a company it had backed less than four years ago in its ......
General
Flashback 2017: Top M&As of the year
Merger and acquisition activity in India eased this year, with deal volume falling to a four-year low and several high-profile ......
